Immunocytochemical monitoring of micrometastatic disease: Reduction of prostate cancer cells in bone marrow by androgen deprivation
Open Access
- 16 May 1997
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 71 (4), 521-525
- https://doi.org/10.1002/(sici)1097-0215(19970516)71:4<521::aid-ijc4>3.0.co;2-w
Abstract
Occult dissemination of tumor cells mainly determines the prognosis of patients with primary prostate cancer. The effect of androgen deprivation on micrometastatic tumor cells in these patients is currently unknown. We therefore used an immunocytochemical assay with monoclonal antibodies (MAbs) directed against epithelial cytoskeleton proteins (i.e., cytokeratins) to monitor the concentration of isolated tumor cells in the bone marrow of 36 prostate cancer patients (stage C), who underwent hormonal androgen deprivation with Flutamide and Leuproreline acetate. Tumor cells in cytologic bone marrow preparations were detected using an assay that employed the MAb CK2 directed against cytokeratin (CK) 18 and the alkaline anti‐alkaline phosphatase staining method. Prior to therapy, we detected between 1 and 38 CK‐positive cells per sample of 2 × 104 nucleated cells in 21 patients, while the remaining 15 patients displayed tumor‐free marrow samples. There was no significant correlation between the concentration of CK‐positive cells and the volume of hypo‐echogenic lesions as an indicator of the primary tumor volume or the serum level of prostate‐specific antigen (PSA). After androgen deprivation, 20 of the 21 initially positive patients either became negative (n = 16) or showed at least a reduction in the concentration of CK‐positive cells (n = 4). Moreover, only 2 of the 15 patients with negative pre‐treatment findings became positive. All of the 7 patients with remaining tumor cells in the bone marrow after therapy showed no detectable amounts of PSA in their serum. Our findings suggest that serum PSA concentration is no indicator of micrometastatic disease in bone marrow. Neoadjuvant androgen deprivation appears to eliminate disseminated CK‐positive tumor cells present in bone marrow, a preferred site of overt metastasis in prostate cancer patients. Int. J. Cancer 71:521‐525, 1997.Keywords
This publication has 20 references indexed in Scilit:
- Immunocytochemical Detection of Disseminated Tumor Cells in the Bone Marrow of Patients With Esophageal CarcinomaJNCI Journal of the National Cancer Institute, 1996
- Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumoursEuropean Journal Of Cancer, 1995
- Detection of Occult Bone Marrow Micrometastases in Patients with Operable Lung CarcinomaAnnals of Surgery, 1995
- Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancerEuropean Journal Of Cancer, 1995
- Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upBritish Journal of Cancer, 1994
- Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma CellsJNCI Journal of the National Cancer Institute, 1993
- Complete androgen blockade in prostate cancer: An overview of randomized trialsThe Prostate, 1992
- Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-upEuropean Journal of Cancer and Clinical Oncology, 1991
- Micrometastatic tumour cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significanceEuropean Journal of Cancer and Clinical Oncology, 1991
- Keratins as biochemical markers of epithelial differentiationTrends in Genetics, 1988